Ronald Kirk Huntsman - 31 May 2022 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ R. Kirk Huntsman
Issuer symbol
VVOS
Transactions as of
31 May 2022
Net transactions value
+$23,560
Form type
4
Filing time
03 Jun 2022, 06:08:33 UTC
Previous filing
28 Feb 2022
Next filing
28 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VVOS Common Stock Purchase $16,240 +8,000 +52% $2.03* 23,500 31 May 2022 Direct F1
transaction VVOS Common Stock Purchase $7,320 +4,000 +17% $1.83* 27,500 01 Jun 2022 Direct
holding VVOS Common Stock 1,740,000 31 May 2022 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in four separate transactions ranging from $2.02 to $2.035 on May 31, 2022. The reporting person undertakes to provide to Vivos Therapeutics, Inc., any security holder of Vivos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2 Shares held by Coronado V Partners, LLC, of which the reporting person is a member and manager.